Open Orphan article published in Drug Discovery Today

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for a vaccine candidate for respiratory syncytial virus (RSV). Bavarian Nordic’s MVA-BN RSV was granted the designation, which is designed to expedite the development

Each journey begins at a starting point, and we believe that few journeys are as exciting as developing a drug. In order to succeed and reach your destination, you need a solid roadmap, the drug development

Healthy, young people who were intentionally exposed to the coronavirus SARS-CoV-2 developed mild symptoms — if any — in a first-of-its-kind COVID-19 human-challenge study. Such trials present a unique opportunity to study viral infections in detail

Malaria is often quoted as the most common disease in all human history. With the earliest recorded cases are estimated to have been around 10,000 years ago, when a small plasmodium parasite made a jump across

As the Omicron variant of the coronavirus continues to sweep across the United States, another important question has emerged for scientists worldwide: Will more transmission equal more long COVID cases? The rate of hospitalization has also

A little-known disease called RSV with symptoms similar to a cold and elements easily mistaken for Covid puts thousands of UK kids in hospital each year – now warnings are being put out by the British Lung

Non-clinical testing is conducted throughout all phases of drug development to assess the safety profile and pharmacokinetic/toxico- kinetic (PK/TK) characteristics of drug candidates. If performed well, it can identify key ‘knock-out’ criteria, maximizing the chances of

Pharmacokinetics (PK) is generally referred to as ‘what the body does to the drug’ versus ‘what the drug does to the body’ (pharmacodynamics [PD]). Pharmacokinetics describes the fate, or time course, of an administered drug within

The Challenge Respiratory syncytial virus (RSV) is the single most important cause of lower respiratory tract infection (LRTI) in infants and young children worldwide and can cause LRTI in elderly and immunocompromised patients; it is associated

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO